Non Hodgkin Lymphoma Clinical Trial

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Summary

An open-label, global, multi-center study to evaluate the safety and pharmacokinetics of venetoclax monotherapy, to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of venetoclax in pediatric and young adult participants with relapsed or refractory malignancies.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants must have relapsed or refractory cancer.
Participants must have adequate hepatic and kidney function.
Participants less than or equal to 16 years of age must have performance status of Lansky greater than or equal to 50% and participants greater than 16 years of age must have performance status of Karnofsky greater than or equal to 50%.
Participants with solid tumors (with the exception of neuroblastoma) must have adequate bone marrow function in Part 1.
For the fifth cohort during Part 2 Cohort Expansion, participants with solid tumors must have evidence of BCL-2 expression (except participants with TCF3-HLF ALL).

Exclusion Criteria:

Participants with primary brain tumors or disease metastatic to the brain.
Participants who have central nervous system (CNS) disease with cranial involvement that requires radiation.

Participants who have received any of the following within the listed time frame, prior to the first dose of study drug

Inotuzumab ozogamicin or gemtuzumab ozogamicin within 30 days
Biologic agent (i.e., antibodies) for anti-neoplastic intent within 30 days or 5 half-lives whichever is shorter.
CAR-T infusion or other cellular therapy within 30 days
Anticancer therapy including chemotherapy, radiation therapy, targeted small molecule agents, investigational agents within 14 days or 5 half-lives, whichever is shorter (Exceptions: Ph+ALL participants on Tyrosine Kinase Inhibitor (TKI) at Screening may enroll and remain on TKI therapy to control disease and TCF3-HLF ALL participants are allowed to have received chemotherapy within 14 days or 5 half-lives, whichever is shorter).
Steroid therapy for anti-neoplastic intent within 5 days (with the exception of TCF3-HLF ALL participants).
Requires ongoing hydroxyurea (hydroxyurea permitted up to first dose)
Participants who are less than 100 days post-transplant, or greater than or equal to 100 days post-transplant with active graft versus host disease (GVHD), or are receiving immunosuppressant therapy within 7 days prior to first dose of study drug.
Participants who are less than 6 weeks post-131 I-metaiodobenzylguanidine (mIBG) therapy.

Participants who have received the following within 7 days prior to the first dose of study drug:

Strong and moderate Cytochrome P450 3A (CYP3A) inhibitors (Part 1 Dose Determination);
Strong and moderate CYP3A inducers (Part 1 Dose Determination and Part 2 Cohort Expansion).
Participants who have not recovered from clinically significant adverse effect(s)/toxicity(s) of the previous therapy (Exception: Chemotherapy induced side effects that are expected to return to baseline in TCF3-HLF ALL participants).
Participants who have active, uncontrolled infections.

Participants with malabsorption syndrome or any other condition that precludes enteral administration.

Participants with recent positive test for SARS-CoV-2 (COVID-19) and no follow up test with negative result cannot be enrolled. Participants with contact to persons with COVID-19 and participants with signs and symptoms for COVID-19 infection must be tested before enrolling.

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

143

Study ID:

NCT03236857

Recruitment Status:

Active, not recruiting

Sponsor:

AbbVie

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 31 Locations for this study

See Locations Near You

Univ California, San Francisco /ID# 163460
San Francisco California, 94143, United States
Children's Hospital Colorado /ID# 161551
Aurora Colorado, 80045, United States
Children's Healthcare of Atlan /ID# 161552
Atlanta Georgia, 30322, United States
Dana-Farber Cancer Institute /ID# 163440
Boston Massachusetts, 02215, United States
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 163444
New York New York, 10065, United States
Cincinnati Children's Hospital /ID# 161550
Cincinnati Ohio, 45229, United States
Children's Hospital of Philadelphia /ID# 163445
Philadelphia Pennsylvania, 19104, United States
St Jude Children's Research Hospital /ID# 163447
Memphis Tennessee, 38105, United States
Primary Children's /ID# 164399
Salt Lake City Utah, 84113, United States
Seattle Children's Hospital /ID# 163459
Seattle Washington, 98105, United States
Medical College of Wisconsin /ID# 163461
Milwaukee Wisconsin, 53226, United States
Sydney Children's Hospital /ID# 163148
Randwick New South Wales, 2031, Australia
Queensland Children's Hospital /ID# 163146
South Brisbane Queensland, 4101, Australia
Women and Childrens Hospital /ID# 163147
North Adelaide South Australia, 5006, Australia
Royal Children's Hospital /ID# 163104
Parkville Victoria, 3052, Australia
Hospital for Sick Children /ID# 163726
Toronto Ontario, M5G 1, Canada
CHU Sainte-Justine /ID# 163725
Montreal Quebec, H3T 1, Canada
AP-HM - Hopital de la Timone /ID# 161465
Marseille CEDEX 05 Bouches-du-Rhone, 13385, France
Centre Leon Berard /ID# 163707
Lyon CEDEX 08 Rhone, 69373, France
AP-HP - Hopital Armand-Trousseau /ID# 163728
Paris , 75012, France
Robert Debre Hopital, FR /ID# 161464
Paris , 75019, France
CHU Toulouse - Hôpital des enfants /ID# 163727
Toulouse CEDEX 9 , 31059, France
Universitaetsklinikum Freiburg /ID# 164206
Freiburg Baden-Wuerttemberg, 79106, Germany
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 161729
Kiel Schleswig-Holstein, 24105, Germany
Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 161730
Berlin , 13353, Germany
Universitaetsklinikum Essen /ID# 164207
Essen , 45147, Germany
Erasmus MC - Sophia /ID# 161579
Rotterdam , 3015 , Netherlands
Prinses Maxima Centrum /ID# 162670
Utrecht , 3584 , Netherlands
Kinderspital Zurich - Eleonorenstiftung /ID# 163037
Zurich Zuerich, 8032, Switzerland
Great Ormond Street Hospital for Children /ID# 169238
London London, City Of, WC1N , United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust /ID# 162938
Newcastle Upon Tyne , NE7 7, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

143

Study ID:

NCT03236857

Recruitment Status:

Active, not recruiting

Sponsor:


AbbVie

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.